ID | 1397 | |
PMID | 7700663 | |
Year | 1995 | |
Sequence | Botulinum neurotoxin A light chain (PFVNKQF NYKDPVNGVDIAYIKIPN AGQMQPVKAFKIHNKI WVIPERDTFTNPEEGD LNPPPEAKQVPVSYY DSTYLSTDNEKDNYLK GVTKLFERIYSTDLGR MLLTSIVRGIPFWGG STIDTELKVIDTNCIN VIQPDGSYRSEE LNLVIIGPSADIIQFE CKSFGHEVLNLTRNGY GSTQYIRFSPDFT FGFEESLEVDTNPLL | |
Name | Botulinum toxin type A | |
Length | 1295 | |
N-Terminal Modification | Free | |
C-Terminal Modification | Free | |
Linear/ Cyclic | Cyclic (C429-453, C1234-1279) | |
Chirality | L | |
Chemical Modification | None | |
Origin of Peptide | Neurotoxic protein produced by the bacterium Clostridium botulinum. It is also produced commercially for medical, cosmetic and research use. | |
Nature of Peptide/Cargo | Potent inhibitor of cholinergic motor nerves. | |
Mechanism | Not mentioned | |
Cargo Sequence/Structure | None | |
Name of cargo | Not applicable | |
Assay | Weights of the nasal secretion were collected and compared. | |
Enhancer | None | |
Properties of enhancer | Not applicable | |
Concentration | 50 units of type A botulinum toxin (total volume 4 cm 3,conc 1.25 units/0.1 cm) | |
Incubation time | 6 days | |
Tissue permeability (value with units) | Topically applied botulinum toxin reduced neurally evoked rhinorrhea by an average of 41%. | |
Tissue Sample | Nasal cavity of male mongrel dogs | |
Ex vivo/In vivo/In vitro | in vivo | |
STRUCTURE |
| |
SMILES | N.A. |